Generic selectors
Exact matches only
Search in title
Search in content
Search in posts
Search in pages
Filter by Categories
Analysis
Comment
Deals
Events
News
People

Exit

Grail spins back into Illumina for $8bn
Two weeks after filing to go public, Grail has instead accepted an $8bn acquisition offer from Illumina, which had spun off the cancer diagnostics technology developer five years ago.
Zhonggu Logistics to move onto stock exchange
Zhonggu Logistics has filed for a $218m on the Shanghai Stock Exchange, providing exits to Zhonggu Shipping and SoftBank.
Roche fires up $448m Inflazome acquisition
Novartis-backed Inflazome, which advances University of Queensland and Trinity College Dublin research to develop treatments for inflammation, has been bought by Roche for $448m.
Compass navigates IPO
Compass Pathways has raised more than $127m in an upsized initial public offering that provided an exit to Otsuka Pharmaceuticals.
Amwell rams its way to $742m IPO
The telehealth system provider is going public in an $742m upsized offering that will enable Philips, Allianz, Teva and Takeda to exit.
Outset Medical pumps IPO up to $278m
The kidney dialysis technology provider has added about $36m to close its initial public offering, it shares having more than doubled in price.
Kuaishou to cook up $5bn IPO
Tencent is the largest shareholder of short-form video app developer Kuaishou, which is reportedly looking to boost its valuation to $50bn in a January offering.
JFrog jumps IPO up to $509m
Dell's stake in the software release technology provider is sized at almost $490m following an initial public offering in which it floated well above its range.

Other News

Pure Storage organises $370m Portworx purchase
The data services software provider had raised more than $55m from investors including NetApp, Cisco Investments, Hewlett Packard Enterprise and GE Ventures.
Metacrine shows mettle in $85m IPO
Lilly Asia Ventures achieved an exit as the gastrointestinal and liver disease drug developer priced its initial public offering in the middle of its range.
Snowflake hits public markets in $3.36bn IPO
Salesforce Ventures will invest another $250m as the data management software provider floated above its range at a valuation just short of $29bn.
Opendoor welcomes reverse merger
Lennar, SoftBank, Access Industries and Alphabet are set to score exits from the real estate transaction manager, valued at $4.8bn in the deal.
Outset Medical outpaces expectations in $242m IPO
Baxter International scored an exit as dialysis machine developer Outset Medical floated above its range in an upsized offering.
Oncorus goes on to IPO stage
Astellas and Celgene-backed immuno-oncology therapy developer Oncorus has filed to raise up to $86.3m following more than $150m in funding.

Editor's Picks

Amwell rams its way to $742m IPO
The telehealth system provider is going public in an $742m upsized offering that will enable Philips, Allianz, Teva and Takeda to exit.
Snowflake hits public markets in $3.36bn IPO
Salesforce Ventures will invest another $250m as the data management software provider floated above its range at a valuation just short of $29bn.
Opendoor welcomes reverse merger
Lennar, SoftBank, Access Industries and Alphabet are set to score exits from the real estate transaction manager, valued at $4.8bn in the deal.
Grail to pour itself on to public markets
Illumina's cancer diagnostics spinoff, which has raised more than $1.9bn in funding, has filed to float on the Nasdaq Global Select Market.
test reg

Login